We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Gastroenterology

Journal Scan / Research · August 27, 2020

Lubiprostone in Patients With NAFLD

The Lancet Gastroenterology & Hepatology


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Gastroenterology & Hepatology
Lubiprostone in Patients With Non-Alcoholic Fatty Liver Disease: A Randomised, Double-Blind, Placebo-Controlled, Phase 2a Trial
Lancet Gastroenterol Hepatol 2020 Aug 14;[EPub Ahead of Print], T Kessoku, K Imajo, T Kobayashi, A Ozaki, M Iwaki, Y Honda, T Kato, Y Ogawa, W Tomeno, S Kato, T Higurashi, M Yoneda, H Kirikoshi, K Kubota, M Taguri, T Yamanaka, H Usuda, K Wada, N Kobayashi, S Saito, A Nakajima

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading